Trial Profile
Phase I/II Study of MM-398 in Combination With Ramucirumab After Platinum Failure in Gastric Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2020 Planned End Date changed from 9 Dec 2022 to 9 Dec 2023.
- 25 Mar 2020 Planned primary completion date changed from 9 Dec 2021 to 6 Apr 2022.
- 25 Mar 2020 Planned initiation date changed from 9 Dec 2019 to 6 Apr 2020.